ArticleNeuro-ophthalmology (Aeolus Press)2026
Disulfiram-Induced Optic Neuropathy: Prognostic Factors, Literature Review and Comparison with Alcohol-Tobacco Induced Optic Neuropathy.
Article in Neuro-ophthalmology (Aeolus Press), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Case Report: Disulfiram-induced optic neuropathy.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Disulfiram is a known cause of toxic optic neuropathy (ON), although there are few cases reported in literature. Our objective is to describe a series of patients with disulfiram-associated ON, and compare them with patients with alcohol-tobacco induced ON. We performed a retrospective cohort of patients with toxic ON, either disulfiram-associated or alcohol-tobacco induced (follow-up: 12 months). Data were extracted from a Spanish tertiary hospital, between 2018 and 2024. Visual acuity (VA) and papillary optic coherence tomography (OCT) were performed at baseline and during the follow-up. A statistical analysis was done, including, Chi-square, Fisher's exact, Mann-Whitney U, and Spearman R tests. Eighteen patients were analyzed (17 males). The mean age of onset was 51.1 years. Seven patients were in active treatment with disulfiram at symptom onset (mean dose received: 204 g). Patients with active disulfiram use had a lower baseline VA (20/77 vs 20/50,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.